The clinical uses of inhaled nitric oxide (iNO) have evolved over the decades as more and more data reveal its benefits (and potential benefits) for a range of cardiopulmonary disorders.
By Charles V. Pollack, Jr, MD, FACEP, FAHA
Clinician Scientist, Department of Emergency Medicine, University of Mississippi Medical Center
Chief Medical Officer, Vero Biotech
Nitric oxide (NO) is a compound produced by many cells of the body, including the vascular endothelial cells of the lung. In particular, NO relaxes vascular smooth muscle by increasing intracellular levels of cyclic guanosine 3’,5’- monophosphate (cGMP), which then leads to vasodilation of the pulmonary capillaries. Beyond the lung, NO is an essential signaling molecule and is also involved in a number of important and diverse physiologic processes throughout the body, including modulating immunological host defense and inhibiting platelet aggregation. The effects of exogenous NO are best understood in lung physiology. Inhaled nitric oxide (iNO) produces selective pulmonary vasodilation and reduces the pulmonary vascular resistance (PVR) associated with pulmonary hypertension (PH), preferentially increasing the partial pressure of arterial oxygen (PaO2) in better ventilated areas of the lung. This action redistributes pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios towards regions with normal ratios. Fortunately, because of efficient scavenging and inactivation by hemoglobin, iNO has a minimal effect on the systemic vasculature and therefore only rarely causes hypotension, in important contrast to intravenously infused vasodilators.
The vasodilator effects of endogenous, endothelial-derived NO were first recognized in 1987, and the first description of iNO for the treatment of PH was presented at the American Thoracic Society conference in 1988, by Higenbottam, who delivered the talk “Inhaled endothelium-derived relaxing factor (EDRF) in primary pulmonary hypertension.”1 In 1991, Lancet published the study, showing that 40 parts per million (ppm) iNO selectively reduced pulmonary artery pressure with no significant changes in systemic pressure.2
The pluripotential therapeutic impact of iNO has been and continues to be further described since then, but while it is currently used in many clinical settings in children and adults, the only FDA-approved indication of iNO, which was granted in 1999, is to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure (HRF) associated with clinical or echocardiographic evidence of pulmonary hypertension, termed “PPHN” for persistent pulmonary hypertension in the newborn.
How Is iNO Used in the Hospital Today?
Approximately 35,000 term and near-term neonates require mechanical ventilation because of HRF, which is commonly caused by PPHN.3 Avoiding high levels of inhaled oxygen and airway pressures is important in this population to limit the incidence of mortality, chronic lung disease (bronchopulmonary dysplasia, or BPD), and serious neurological complications. The numerous risks associated with ECMO including hemorrhage, infection, ischemia, neurological deficits, are well-documented. Studies have shown that iNO, usually administered at a starting dose of 20 ppm, can improve these outcomes in many infants.
With iNO available in the hospital, however, there have been notable increases in use outside the neonatal intensive care unit, particularly in the cardiac catheterization laboratory and in the perioperative management of patients undergoing major cardiothoracic surgery.
In the cath lab, iNO at 20-40 ppm is used for vasoreactivity testing during right heart catheterization to guide therapy for PH.4 Once the PH diagnosis is confirmed by pulmonary artery (PA) pressure measurements, 100% oxygen is administered to the patient for five minutes, followed by reassessment of PA pressures. If pressures normalize with oxygen alone, further testing need not be performed, and the patient’s PH is treated simply with supplemental oxygen. If the oxygen challenge does not reduce PA pressure, acute vasodilator testing with iNO is often performed, and if PA pressures decrease, the patient is considered an “acute responder.” This designation guides the path to possible transplant in some cases, and further chronic PH therapeutics, which may include calcium channel blockers or various combinations of prostacyclin pathway agonists, endothelin receptor antagonists, and NO-cGMP enhancers. However, acute exacerbations may prompt administration of iNO—this time as therapy, not as a diagnostic challenge.
In the perioperative setting, iNO at 10-30 ppm is used to support oxygenation in patients undergoing surgeries up to and including heart transplant, lung transplant, and implantation of left ventricular assist devices (LVADs).5 In cardiac applications, including transplants, PH can lead to right-sided heart failure and early death. Inhaled NO can reduce right ventricular stroke work while not reducing systemic blood pressure. In lung transplantation, iNO is administered in an effort to attenuate ischemia-reperfusion injury, which is an early cause of transplant rejection. Similarly, after LVAD placement, iNO-driven reductions in RV afterload can result in increased left ventricular (LV) filling, LVAD flow, and overall cardiac output. In orthotopic liver transplantation, studies have shown that iNO decreases hepatocyte apoptosis, limits increases of hepatic transaminases, enhances recovery of coagulation factors, and be a treatment modality for hepatopulmonary syndrome.
Additional Uses of iNO Require Further Study
Another potential use of iNO therapy, for which past studies have had inconsistent and conflicting results, is for acute respiratory distress syndrome (ARDS).6,7 Pulmonary hypertension is a hallmark of ARDS, as is V/Q mismatch; the PH contributes to pulmonary edema and RV overload. All of these pathophysiologic features point to a good likelihood of benefit from iNO, and many early studies showed improvement in pressure and oxygenation parameters, but no improvement on survival rates among patients with ARDS. These studies, however, predated the use of lung-protective ventilation that has since been shown to be beneficial in these patients. More recent studies using this ventilation approach and iNO, mostly in pediatric patients, have shown clearer benefit as measured by both days of mechanical ventilation and ECMO-free survival. Evidence showing a benefit of iNO in ARDS in adults continues to accumulate slowly, but large randomized trials are needed to determine a potential impact on survival.
There are few known safety concerns about the use of iNO. A primary issue is the phenomenon of “rebound PH” upon abrupt decease in dose or discontinuation of iNO, which can lead to hypoxia, decreased cardiac output and systemic hypotension, and increased intrapulmonary right-to-left shunting. Weaning protocols for the dose of iNO coupled with responsive oxygen supplementation greatly reduce the risk of rebound.
Although all unusual, clinicians should be aware of these other safety issues that have been related to the use of iNO:
- Methemoglobinemia: iNO can combine with hemoglobin to form nitrosylhemoglobin, which is rapidly oxidized to form methemoglobin (metHb), which when present in excessive quantities (generally > 15-20% of total hemoglobin) can cause tissue hypoxia. The enzyme metHb reductase converts metHb back to hemoglobin that is available for oxygen carrying. Because neonates have reduced activity of this enzyme, they may be at greater risk for developing clinically significant methemoglobinemia during iNO therapy than are adults. If identified before evidence of hypoxia (such as cyanosis) develops, downward titration of iNO usually allows the methemoglobinemia to clear, but if levels are particularly high or the patient is notably symptomatic, a dose of 1–2 mg/kg of methylene blue intravenously is advised.8
- Accumulation of nitrogen dioxide (NO2): NO is unstable in air and will be directly converted to NO2, which is toxic to the respiratory tract at exposures above 5 ppm. Interestingly, most of the toxicologic work on NO2 was performed because it is a major constituent of urban air pollution. At toxic doses, NO2 induces airway inflammation and reactivity, as well as alterations in surfactant metabolism. Newer iNO delivery systems monitor for NO2 at the patient interface.9
- Acute kidney injury (AKI): some studies have shown a risk of AKI during iNO therapy, particularly during perioperative periods of substantial physiologic stress. The mechanism of iNO-related AKI is unclear, and other studies have shown little to no risk of AKI or need for new renal replacement therapy after iNO treatment. Perhaps some care in duration of exposure should be exercised in patients who already have renal insufficiency.10
- Effects on platelet aggregation and bleeding time: in addition to modulating vascular tone, NO inhibits platelet adherence to endothelial cells as well as platelet-to-platelet aggregation.11 Studies on platelet activity and bleeding time have shown conflicting results; one study of neonates treated with iNO at 40 ppm for PPHN showed a prolonged bleeding time but normal in vitro platelet function. In some adults treated with iNO for ARDS, there was evidence of prolonged bleeding times, inhibition of platelet aggregation, and reduced P-selectin expression and fibrinogen binding, though there was no consistent clinical correlate to these findings.11
Potential for Out-of-Hospital iNO Use
While iNO clearly reduces elevated PVR in most cases of acute pulmonary decompensation due to PH, more sustained use has been inadequately studied. There are reports of therapeutic use of iNO in outpatients with chronic PH, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD), via pulsed delivery in short bursts through nasal oxygen devices with compressed tanks. While this was associated with symptomatic improvement, the process is laborious and the data are sparse; further research on and clinical use of long-term INO have been stymied by the high cost and lack of insurance coverage for off-label applications after FDA approval for PPHN, but interest has resurged recently. Part of the explanation for this data gap has been the logistical and economic consequences of delivering iNO outside the hospital.
Generation and Delivery of NO without Gas Cylinders
The recent approval of a tankless system for generation and delivery of iNO creates an opportunity to evaluate outpatient and home ambulatory use more rigorously.12 Successful home use for a 10-day course was recently described in a patient with known vasoreactive PH who also had comorbid COVID-19 pulmonary syndrome.13
Future Applications of iNO Demand Further Study
The future of iNO therapy extends in two directions: safe and convenient ambulatory/extended use, and additional indications consistent with the broad physiologic activity of NO. Patients with chronic PH, pulmonary fibrosis, and other cardiopulmonary syndromes who might benefit from extended therapy may not be appropriate for prolonged hospitalization. The advent of new, tankless iNO delivery systems could potentially provide a new treatment strategy for these patients. Much work is being performed in this area, but true therapeutic advances will require both proof of concept for a treatment effect as well as optimization of the logistic and economic issues around ambulatory use.
The prospect of new applications for iNO is intriguing. There is biologic plausibility for iNO in the treatment of a number of bacterial and viral infections.14 Endogenously produced NO is an important component of the body’s natural non-specific (innate) and immunological host defenses. Many viral infections elicit vigorous host immune responses, both innate and acquired. These immune responses are frequently successful in controlling and then clearing the virus, using both cellular effectors such as natural killer (NK) cells and cytolytic T lymphocytes, and soluble factors such as interferons.
Antibacterial effects of iNO are likely multi-mechanistic, and include inhibition of proteins in the bacterial respiratory chain, disruptions in bacterial proteins, inhibition of bacterial DNA replication, and inhibition of ribonucleotide reductase. The purported antiviral mechanisms of iNO activity include inhibition of viral entry into cells and, probably due to effects on transcription factors, inhibition of viral replication. It has been proposed that iNO might be an important asset in managing bacterial pathogens that are resistant to multiple conventional antimicrobial agents, and its coincident pulmonary anti-inflammatory effects make it a good candidate for aiding in cystic fibrosis management as well.15 Similarly, infections with otherwise often resistant intracellular pathogens (such as Listeria monocytogenes, Salmonella, and Mycobacterium tuberculosis) may be responsive to NO.16
Antimicrobial activity against several bacteria by NO in vitro has been demonstrated, and antiviral activity has also been described. In particular, in vitro studies have shown that NO functionally inhibits viral replication. In studies spurred by the viral severe acute respiratory syndrome (SARS) outbreak in the early 2000s, NO demonstrated an antiviral effect against the strain of coronavirus (SARS CoV) associated with that disease by significantly inhibiting the viral replication cycle via two distinct mechanisms.17,18 One study (n=14) during the SARS epidemic in 2002-2003 showed that iNO improved arterial oxygenation and enabled the reduction of inspired oxygen therapy and airway pressure support in patients with severe disease.19 In addition, chest radiography showed decreased spread or density of lung infiltrates, and the physiological effects remained after termination of iNO therapy, suggesting not only a pulmonary vasodilator effect, but also a direct effect on the SARS virus, consistent with the in vitro studies. The current COVID-19 pandemic has fostered the launch of numerous iNO trials with widely varying methodologies, target patient cohorts, and dosing regimens.
Other potential uses of iNO include treatment of acute chest syndrome in sickle cell disease and cerebral malaria. Pain crises—particularly acute chest syndrome—in sickle cell disease are often suboptimally managed with conventional analgesics. The pathophysiology of a “vaso-occlusive” pain crisis is the physical, mechanical obstruction of blood vessels by “sickled” red blood cells. It has been postulated that iNO-induced pulmonary vasodilation might improve the flow of sickled cells in these vascular beds and relieve obstruction, pain, and tissue hypoxia.20
Cerebral malaria in children leads to long-term neurocognitive deficits in about one-quarter of survivors. In a randomized, double-blind, placebo-controlled trial of iNO versus placebo gas as an adjunctive therapy for severe malaria conducted in Uganda between 2011 and 2013, the iNO exposure was 80 ppm for up to 72 hours.21 Patients in the iNO arm had a reduced risk of fine motor impairment. These results need to be validated and expanded upon in, again, larger and rigorously controlled trials. The idea that iNO might be neuroprotective, though, is provocative. The mechanism of action of iNO in malaria is presumed to include reduced systemic inflammation and endothelial cell activation, decreased intercellular adhesion molecule-1 (ICAM-1) expression, preserved integrity of the blood–brain barrier, and decreased parasite accumulation in the brain.22
Because NO is such an important and active signaling molecule in multiple organ systems, the potential utility of iNO is broad and likely substantially exceeds its current sole labeled indication. It may soon be determined that iNO has particular indications germane to the catheterization laboratory, the perioperative environment, and management of both hematologic and infectious diseases. With tankless delivery systems, some of these new uses may also be extended into the home care and chronic use settings. Intensive exploration of the diverse therapeutic effects that are biologically plausible is needed, warranted, and is well underway.
Charles V. Pollack, Jr, MD, FACEP, FAHA is a clinician scientist in the Department of Emergency Medicine at the University of Mississippi Medical Center, and chief medical officer of Vero Biotech. For more information contact [email protected].
1 Higenbotham TW, oral presentation, Inhaled endothelium-derived relaxing factor (EDRF) in primary pulmonary hypertension, American Thoracic Society annual meeting 1988.
2 Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
3 Nelin JD, Potenziano JL. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatrics. 2019; https://doi.org/10.1186/s12887-018-1368-4, accessed 6/4/20.
4 Volk KW. The assessment of acute vasoreactivity during right heart catheterizations for the evaluation of pulmonary arterial hypertension. Cath Lab Digest. 2018;26(5).
5 Dabbagh A, Tajbakhsh A, Talebi Z, Rajaei S. Cardiovascular pharmacology in adult patients undergoing cardiac surgery. In Postoperative Critical Care for Adult Cardiac Surgical Patients, Springer 2018, pp 75-142.
6 Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults (Review). 2016;6. https://doi.org/10.1002/14651858.CD002787.pub3
7 Needham DM, Yang T, Dinglas VD, et al. Timing of low tidal volume ventilation and intensive care unit mortality in acute respiratory distress syndrome: a prospective cohort study. Am J Respir Crit Care Med 2015;191:177–185.
8 Ichinose F, Zapol W. Chapter 25 – Inhaled Nitric Oxide—Current Practice and Future Potential Uses and Development. In Nitric Oxide, (Third Edition). Biology and Pathobiology. Ignarro LJ, Freeman BA eds. Academic Press.2017: 339-353.
9 Petit PC, Fine DH, Vasquez GB et al. The Pathophysiology of Nitrogen Dioxide During Inhaled Nitric Oxide Therapy. ASAIO Journal. 2017;63:7-13.
10 Ruan SY, Huang TM, Wu HY, Wu HD, Yu CJ, Lai MS. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit Care. 2015;19:137.
11 Gries A, Herr A,Motsch J, et al. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Haemost 2000; 83:309–15.
12 Genosyl Inhaled Nitric Oxide Delivery System Approved by FDA.https://rtmagazine.com/products-treatment/monitoring-treatment/therapy-devices/genosyl-inhaled-nitric-oxide-fda/
13 Zamanian RT, Pollack CV, Gentile MA et al. Outpatient Inhaled Nitric Oxide in a Patient With Vasoreactive IPAH and COVID-19 Infection. Am J Respir Crit Care Med. 2020 May 5,, online before print. doi: 10.1164/rccm.202004-0937LE
14 Halpenny GM, Mascharak, PK. Emerging Antimicrobial Applications of Nitric Oxide (NO) and NO-Releasing Materials. Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry – Anti-Infective Agents), 2010;9:187-197.
15 Deppisch C, Herrmann G, Graepler-Mainka U et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection. 2016;44:513-520.
16 Jamaati H, Mortaz E, Pajouhi Z et al. Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis.Front. Microbiol. 2017; 8:2008.
17 Åkerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist Å, Mirazimi A. Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology. 2005;79(3):1966-1969.
18 Åkerström S, Gunalan V, Keng CT, Tan Y-J, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1-9.
19 Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. Journal of Infection. 2013;67(6):606-616. doi:10.1016/j.jinf.2013.09.029
20 Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.JAMA. 2003 Mar 5;289(9):1136-42.
21 Mwanga-Amumpaire J, Carroll RW, Baudin E, et al. Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial.Open Forum Infect Dis. 2015 Jul 24;2(3) ofv111. doi: 10.1093/ofid/ofv111
22 Serghides L, Kim H, Lu Z et al. Inhaled Nitric Oxide Reduces Endothelial Activation and Parasite Accumulation in the Brain, and Enhances Survival in Experimental Cerebral Malaria. PLoS One. 2011; 6(11): e27714.